SUMMARY Eighteen patients with Huntington's chorea were examined before and after neuroleptic treatment (haloperidol, pimozide, tiapride) to study the effect of such treatment on hyperkinesia and motor performance. Pimozide and haloperidol improved hyperkinesia; none of the drugs significantly affected motor performance. No correlation was found between the severity of hyperkinesia and motor performance scores, or between hyperkinesia and intelligence score, before and after therapy.
Abnormal involuntary movements are a most distinctive clinical aspect of Huntington's disease. Striatal dopaminergic hyperactivity is supposed to cause abnormal involuntary movements in Huntington's disease. ' Neuroleptic drugs, which act by inhibiting dopaminergic transmission at the synaptic level,2 are the accepted current therapy of abnormal involuntary movements in Huntington's disease.3 Their effect upon abnormal involuntary movements has been evaluated semiquantitatively.4-7 Impairment of motor performance"89 and functional disability7 are other aspects of Huntington's disease. These features have scarcely been considered in relation to neuroleptic treatment, since attention has been focused by different authors on hyperkinesia. Shoulson7 has observed that functional capacities of choreics were not influenced by neuroleptics. The relationship between abnormal involuntary movements and motor ability should be considered in this context.
The aim of our study was to verify (1) the possible correlation between abnormal involuntary movements and motor impairment in Huntington's disease and (2) the effect of neuroleptic drugs on the same parameters.
Eighteen choreic patients, all showing typical abnormal involuntary movements, mental deterioration and with a family history, were examined. No psychotic disturbances were observed in any patient during the study. Informed consent to enter the pharmacological trial was obtained from each patient. Fourteen age-and education-matched normal subjects served as controls in the tests of intelligence and motor performance. Mean age of the patients with Huntington's disease (11 males, 7 females) was 43 9 years (range 31-59); mean disease duration was 4-7 years (range 1-9). Mean age of control subjects (5 males, 9 females) was 39-9 years (range 28-59).
Pimozide, haloperidol and tiapride were used in the pharmacological trial at the dosages reported in table 1, which also gives the number of patients treated with each drug. Each pharmacological trial lasted one month. When a patient was given more than one neuroleptic drug, each drug was given singly and successively, with a 15-day washout period in between. Patients evaluated in the basal condition were either patients who had never been treated with neuroleptic drugs (seven patients) or patients already treated in the past with such drugs but who had been free of therapy for at least one month before the basal evaluation. 
Discussion
Evaluation of the results obtained at basal condition confirmed the overall intellectual deterioration of the choreics" 12 and the impairment of motor abilities which required the execution of rapid sequences and visuomotor coordination.'3 The correlation between the WAIS score and the screw-and-nut test score, and between the screw-and-nut test score and the Gibson score, suggests that cognitive functions and motor dexterity functions may deteriorate at the same time in the established form of Huntington's disease, in relation to the diffuse neuropathological damage of the basal ganglia and the cerebral cortex. '4 The lack of a correlation between motor performance and abnormal involuntary movements showed that the impaired ability to execute complex movements was not related to the severity of abnormal involuntary movements but was a separate and peculiar aspect of the disease. It may therefore be suggested that the overall severity of Huntington's disease is better depicted by intellectual deterioration and motor disorganisation than by the severity of abnormal involuntary movements. This is in agreement with the observation of Shoulson The global motor impairment in Huntington's disease parallels the extensive neuropathological damage that involves the basal ganglia and the frontal cortex. Impairment of repetitive ballistic movement is probably due to basal ganglia damage, whose main function appears to be the automatic execution of acquired motor plans. '9 In contrast, the impairment in the execution of complex motor sequences in Huntington's disease8 is similar to that described by Luria20 in frontal lobe lesions and points to an involvement of the frontal-motor areas, which are fundamental to motor programming. 2' Choreic akinesis is an expression of this global impairment of movement and is present at all stages of the disease. It may even become worse with neuroleptic therapy, as was found in our series (table 4-patient nos 1, 8 and 17) . It is clear that neuroleptic therapy is not indicated in these patients, whose main symptom is akinesia and who may be evolving to the rigid stage of the disease.
